Merck’s anti-viral development., page-11

It’s important to note, as I mentioned in the start of this thread, that this oral anti-viral in human trial (now product) is not a direct competitor as such to Starpharma (at the moment) as this product is aimed at treating Covid-19 post-infection rather than preventative.

But you’re right it certain does highlight what big gorilla pharmaceutical companies can do, and quickly. Starpharma needs to drive partnerships. Sadly, it would seem very clear from our ASX releases that we were sharing our Viraleze concept and data with major companies over a year ago.

Why no partnership? Either the big players said thanks but no thanks or alternatively CEO Jackie thought she could drive higher profits from keeping Viraleze in house. Yeah … nah.